VSIR and endometrial cancer: However, the regulatory mechanism of VISTA in endometrial cancer is still unclear, and further studies are needed to enlighten the immunomodulatory mechanism of VISTA, as well as the prognostic impact and mechanism of anti-VISTA antibodies, to verify that VISTA can be used as a new biomarker and provide a new direction for immunotherapy of endometrial cancer.